Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid)

Journal of Endocrinological Investigation

Volumn 29, Issue 6, 2006, Pages 563-567

  Davì, Maria Vittoria ^a   Bodei, L ^b   Francia, G ^a   Bartolomei, M ^b   Oliani, C ^a   Scilanga, L ^a   Reghellin, D ^a   Falconi, M ^a   Paganelli, G ^b   Lo Cascio, V ^a   Ferdeghini, M ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

90Y DOTATOC; Carcinoid crisis; Receptor radionuclide therapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE N,N',N'',N''' TETRAACETIC ACID Y 90; ALPHA INTERFERON; BETAMETHASONE SODIUM PHOSPHATE; CHLORPHENIRAMINE MALEATE; CORTICOSTEROID; DEXAMETHASONE; FLUOROURACIL; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; OCTREOTIDE; OXATOMIDE; PROMETHAZINE; RADIOISOTOPE; RANITIDINE; STREPTOZOCIN; UNCLASSIFIED DRUG;

AGED; ANOREXIA; ARTICLE; BONE MARROW TOXICITY; BRONCHUS TUMOR; CARCINOID SYNDROME; CASE REPORT; CLINICAL PROTOCOL; DIARRHEA; DISEASE SEVERITY; EYE EDEMA; FACE; FLUSHING; FOLLOW UP; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LIP; LIVER METASTASIS; LIVER SURGERY; MALE; NAUSEA; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; PROTECTION; REMISSION; SIDE EFFECT; SYMPTOM; TRUNK;

EID: 33746720069     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03344149     Document Type: Article

References (14)

1. Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999, 11: 858-8.
2. Sarmiento JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 2003, 12: 231-42.
3. Kinney MA, Warner ME, Nagorney DM, et al. Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumors. Br J Anaesth 2001, 87: 447-52.
4. Lamberts SW, Van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996, 334: 246-54
5. Oberg K, Kvols L, Chaplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004, 15: 966-73.
6. Garland J, Buscombe JR, Bouvier C, et al. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience. Aliment Pharmacol Ther 2003, 17: 437-44.
7. Ricci S, Antonuzzo A, Galli L, et al. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol 2000, 23: 412-5.
8. Bodei L, Cremonesi M, Grana C, et al. Receptor radionuclide therapy with 90Y-[DOTA]°-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2004, 7: 1038-46.
9. De Jong M, Valkema R, Jmar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002, 32: 133-40.
10. Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002, 43: 610-6.
11. Kaltas GA, Besser GM, Grossman AB. The diagnosis and management of advanced neuroendocrine tumors. Endocr Rev 2004, 25: 458-511.
12. Chinol M, Bodei L, Cremonesi M, Paganelli G. Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3- octreotide: The experience of European Institute of Oncology. Sem Nucl Med 2002, 32: 141-7
13. Paganelli G, Zoboli S, Cremonesi M, et al. Receptor mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3- octreotide. Eur J Nucl Med 2001, 28: 426-34.
14. Bodei L, Cremonesi M, Zoboli S, et al. Receptor-mediated radionuclide therapy with (90)Y-DOTATOC in association with amino acid infusion: A phase I study. Eur J Nucl Med 2003, 30: 207-16.